Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease

Petar Podlesniy1, Dolores Vilas2, Peggy Taylor3

  • 1Neurobiology Unit, Institut d'Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.

Insights

High mitochondrial DNA in cerebrospinal fluid (CSF) distinguishes LRRK2-related Parkinson's disease from idiopathic forms. This finding suggests different neurodegenerative pathways in these Parkinson's disease subtypes.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Mitochondrial DNA (mtDNA) plays a crucial role in mitochondrial function.
  • Altered mtDNA regulation is observed in both idiopathic and familial Parkinson's disease (PD).
  • Investigating mtDNA differences can elucidate distinct pathogenic mechanisms in PD subtypes.

Purpose of the Study:

  • To compare cell-free mitochondrial DNA (cf-mtDNA) content in cerebrospinal fluid (CSF) between idiopathic PD and LRRK2-related PD.
  • To determine if cf-mtDNA levels can differentiate between these two forms of Parkinson's disease.
  • To explore the association of CSF α-synuclein levels with idiopathic and LRRK2-related PD.

Main Methods:

  • Measured cf-mtDNA concentration in 98 CSF samples using digital droplet polymerase chain reaction (ddPCR).
  • Analyzed samples from LRRK2(G2019S) mutation carriers with PD, asymptomatic LRRK2(G2019S) carriers, idiopathic PD patients, and non-carrier relatives.
  • Quantified CSF α-synuclein concentrations.

Main Results:

  • LRRK2(G2019S) mutation carriers with PD showed significantly higher CSF cf-mtDNA concentrations compared to asymptomatic carriers and idiopathic PD patients.
  • Idiopathic PD patients exhibited lower CSF α-synuclein levels compared to LRRK2-related PD.
  • Asymptomatic LRRK2(G2019S) carriers had higher cf-mtDNA levels than non-carrier relatives.

Conclusions:

  • Elevated CSF cf-mtDNA levels are a potential biomarker distinguishing LRRK2-related PD from idiopathic PD.
  • These findings suggest distinct underlying biochemical pathways in the neurodegeneration of idiopathic and LRRK2-related Parkinson's disease.
  • CSF cf-mtDNA and α-synuclein levels may serve as differential diagnostic markers for Parkinson's disease subtypes.